Multiple System Atrophy: Advances in Diagnosis and Therapy

研究成果: ジャーナルへの寄稿総説査読

5 被引用数 (Scopus)

抄録

This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

本文言語英語
ページ(範囲)13-21
ページ数9
ジャーナルJournal of Movement Disorders
16
1
DOI
出版ステータス出版済み - 01-2023

All Science Journal Classification (ASJC) codes

  • 神経学
  • 臨床神経学

フィンガープリント

「Multiple System Atrophy: Advances in Diagnosis and Therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル